In another clinical trial reported recently, IL-15 was subcutaneously administered to patients with melanoma, RCC, non-small cell lung cancer (NSCLC) or squamous cell head and neck carcinoma.45 The maximum tolerated dose of IL-15 administered subcutaneously was significantly higher than the dose that was feasible by intravenous bolus injection, and reached 3.0 μg/kg per day. Here, IL15 is linked to non-small cell lung carcinoma.